Osteotec, a Newbury, U.K.-based manufacturer and distributor of specialized medical devices, has announced an exclusive agreement to distribute Cerapedics Inc.’s i-FACTOR bone graft portfolio in the U.K. and Ireland. This agreement expands Osteotec’s offerings, enabling healthcare professionals to access Cerapedics’ i-FACTOR Bone Graft Putty and i-FACTOR Bone Graft FLEX FR products for spine procedures.
The partnership highlights Osteotec’s commitment to enhancing surgical outcomes and improving patient care in bone repair. Cerapedics, headquartered in Westminster, is recognized as a global leader in orthopaedics, with its i-FACTOR portfolio featuring the proprietary P-15 Osteogenic Cell Binding Peptide, which accelerates new bone formation.
“At Osteotec, we are committed to delivering best-in-class solutions that empower surgeons to achieve optimal patient outcomes,” said Dean Stockwell, sales and marketing director at Osteotec. “Our partnership with Cerapedics enhances our ability to meet the evolving needs of our customers by providing access to advanced biologics.”
The distribution agreement, effective Dec. 1, 2024, aims to significantly increase sales and revenue while accelerating growth. The collaboration combines Cerapedics’ innovative product design with Osteotec’s market expertise to promote broader adoption of i-FACTOR products in the region.
“This partnership is an important step in our global growth strategy,” said Stewart Jefferson, Cerapedics general manager, international.
